Amanote Research
Register
Sign In
Exploring Selective Inhibition of the First Bromodomain of the Human Bromodomain and Extra-Terminal Domain (BET) Proteins
doi 10.1021/acs.jmedchem.5b01708.s001
Full Text
Open PDF
Abstract
Available in
full text
Date
Unknown
Authors
Unknown
Publisher
American Chemical Society (ACS)
Related search
Inhibition of Bromodomain and Extra-Terminal Proteins (BET) as a Potential Therapeutic Approach in Haematological Malignancies: Emerging Preclinical and Clinical Evidence
Therapeutic Advances in Hematology
Hematology
Bromodomain and Extra-Terminal Protein Inhibition Attenuates Neutrophil-Dominant Allergic Airway Disease
Scientific Reports
Multidisciplinary
Suppression of Interferon Β Gene Transcription by Inhibitors of Bromodomain and Extra-Terminal (BET) Family Members
Biochemical Journal
Biochemistry
Cell Biology
Molecular Biology
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials
Journal of Medicinal Chemistry
Drug Discovery
Molecular Medicine
BET Bromodomain Proteins Are Therapeutic Targets in CRPC
Cancer Discovery
Oncology
Bromodomain and Extraterminal (BET) Proteins Regulate Biliary-Driven Liver Regeneration
Journal of Hepatology
Hepatology
Pharmacological Inhibition of Bromodomain-Containing Proteins in Inflammation
Cold Spring Harbor perspectives in biology
Biochemistry
Genetics
Molecular Biology
BET Bromodomain Inhibition Releases the Mediator Complex From Select Cis-Regulatory Elements
Cell Reports
Biochemistry
Genetics
Molecular Biology
Applying 89Zr-Transferrin to Study the Pharmacology of Inhibitors to BET Bromodomain Containing Proteins
